Conference call regarding information on the offer made to Vivoline’s shareholders

Invitation to attend XVIVO Perfusion’s conference call regarding information on the offer made to Vivoline’s shareholders. The presentation will be held in Swedish.

This press release may not, directly nor indirectly, be distributed in or to, Australia, Hong Kong, Japan, Canada, New Zeeland, South Africa or the U.S or in any other country where making of the Offer, distribution of this press release or acceptance of the Offer would be contrary to applicable laws or rules or would require further offering documentation or registration or any other measures in addition to what is required by Swedish law.

Time: Thursday, May 19, 2016 at 2.00 p.m. CET

Registration can preferably be done in advance under the following link:

or shortly before time of the conference starts on:
Sweden dial in number: +46 (0)8-503 364 34
International dial in number: +44 (0) 1452 555566
Conference name: XVIVO Perfusion, conference ID:

Participants from XVIVO Perfusion:
Magnus Nilsson, CEO
Christoffer Rosenblad, CFO

Shortly before the conference call, slides will be available at the company web page,

May 17, 2016
XVIVO Perfusion AB (publ)

For further information please contact:

Christoffer Rosenblad, CFO, +1 720 616 2101,

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.


XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in the USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker symbol XVIVO. More information can be found on the website The Certified Adviser is Redeye,

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: Website:



Documents & Links